TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04451655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Description: This study aims to explore the hypothesis that diabetic patients undergoing coronary artery bypass graft (CABG) surgery receiving intravenous continuous insulin infusion (CII) for tight glycemic control (110-149 mg/dl) protocol during the intraoperative period would have improved intraoperative glycemic stability, efficacy and consistency compared to patients receiving conventional glycemic control (150-180 mg/dl) protocol during the intraoperative period
Study: NCT03174821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Blood glucose management device
Study: NCT00995345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT02071615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00668759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant Injection
Description: 10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
Study: NCT02336594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study: NCT00668759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Injection:
Description: 60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
Study: NCT01649193

Intervention type: OTHER
Intervention: Pulmonary rehabilitation
Description: An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
Study: NCT00744861

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exospine sham
Description: Inactive Exospine LIPUS device (dual transducers)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exospine
Description: Active Exospine LIPUS device (dual transducers)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exogen 4000+
Description: Active Exogen LIPUS device (single transducer)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Exogen 4000+ sham
Description: Inactive Exogen 4000+ LIPUS device (single transducer)
Study: NCT04897568

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient decision aid
Description: Each subject will receive an informational flyer describing lung cancer screening options and smoking cessation from a trained person on the medical staff at each clinic. Staff will lead a shared decision-making discussion with the patient.
Study: NCT02858726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CR845 1.5mcg/kg
Description: IV medication delivered three times/week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV medication delivered three times/week
Study: NCT02304068

Intervention type: OTHER
Group type: OTHER
Intervention: Home monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital assessment
Study: NCT04329416

Intervention type: OTHER
Group type: OTHER
Intervention: Predicted depth of insertion
Description: A left-sided double-lumen tube was introduced beyond the vocal cords when the train-of-four stimulation of the ulnar nerve revealed 1 or 2 twitches, the stylet was removed, the double-lumen tube was rotated 90° counterclockwise and then advanced blindly to the predicted depth of insertion.

Intervention type: OTHER
Group type: OTHER
Intervention: Optimized depth of insertion
Description: The optimal position of the double-lumen tube, defined as the inflated endobronchial cuff is placed in the left main bronchus just below the carina without herniation, which was confirmed using a flexible bronchoscope in both supine and lateral decubitus positions.

Intervention type: OTHER
Group type: OTHER
Intervention: Adjustment of depth of insertion
Description: If the endobronchial cuff was placed too deeply or too proximal, subsequently, the double-lumen tube was withdrawn or advanced, respectively, using the flexible bronchoscope until the optimum position of the double-lumen tube was achieved.
Study: NCT01158326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resfenol
Description: Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.~10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of oral placebo every 6 hours for 48 hours
Study: NCT00537199

Intervention type: OTHER
Group type: OTHER
Intervention: Visual Examination
Description: Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.

Intervention type: DRUG
Group type: OTHER
Intervention: OraTest
Description: Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
Study: NCT00272649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-003
Description: Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
Study: NCT03856905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program
Description: It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy program
Description: It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: It will consist of gentle stretching exercises for spastic muscles, facilitation of muscle contraction for the anti-spastic muscles, proprioceptive training, balance and postural control exercises, neurodevelopmental techniques, and gait training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: It is an electromagnetic coil lithotripter (Modulith SLK; Storz Medical AG, Tagerwillen, Switzerland) provided with in-line ultrasound, radiographic, and computerized aiming (Lithotrack system; Storz Medical AG). The energy applied will be 0.030 mJ/mm2. The frequency will be 5 Hz, with a pressure of 1.5 bars, burst mode.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: It is a highly advanced medical device that consists of a battery-operated, single-channel electrical stimulator, two electrodes, and electrode leads with a cuff holds the system in place. The stimulation parameters will include pulse frequency (16-33 pulses per second), pulse width (25-300 µs) to produce a desired movement as close to normal as possible at the ankle during gait.
Study: NCT00576303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Study: NCT00601900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT02951117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Tablet or intravenous infusion
Study: NCT01680276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PBS based staff training
Description: Please see published study protocol for more information:~http://www.biomedcentral.com/1471-244X/14/219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: http://www.biomedcentral.com/1471-244X/14/219

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: http://www.biomedcentral.com/1471-244X/14/219
Study: NCT00757718

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Appliance
Description: Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
Study: NCT01817036

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D per pill

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D per pill

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D per pill

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 400 IU vitamin D per pill
Study: NCT03182036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable pulsed oxygen
Description: Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
Study: NCT05001919

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: GTR
Description: intrabony defects treated by surgery and bone graft +collagen membrane

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: concentrated growth factor
Description: intrabony defects treated by surgery and bone graft +concenrated growth factor membrane
Study: NCT04436055

Intervention type: OTHER
Intervention: No Intervention will be used
Description: Since this is an observational study, there are no interventions.
Study: NCT00315120

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A. Active OMT and active UST
Description: Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: B. Sham OMT and active UST
Description: Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: C. Active OMT and sham UST
Description: Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: D. Sham OMT and sham UST
Description: Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
Study: NCT04423484

Intervention type: OTHER
Intervention: Data collection
Description: Clinical stage, treatment given and observations of toxicity if any, outcome following treatment and follow up.
Study: NCT02161653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone plus Metadoxine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline plus Metadoxine
Study: NCT01048788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
Study: NCT00562913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
Study: NCT04009226

Intervention type: OTHER
Intervention: Patient Registry
Description: Participants who have volunteered to participate will complete various questionnaires relating to their condition.
Study: NCT01189006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
Study: NCT02533908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl intranasal
Description: fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% intranasal
Description: Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
Study: NCT02465086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of linguistic recursion
Description: Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
Study: NCT03203018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive workshop based on community specific needs
Description: Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results.
Study: NCT04538248

Intervention type: OTHER
Intervention: Combined rehabilitation during hemodialysis
Description: Combined rehabilitation during hemodialysis

Intervention type: OTHER
Intervention: Combined rehabilitation during hemodialysis
Description: Combined rehabilitation during hemodialysis
Study: NCT03284502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573, cobimetinib
Description: Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573, cetuximab
Description: Regimen: twice daily (BID), continuous dosing for HM95573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573, cobimetinib
Description: Regimen: Recommended dose (RD) and schedule selected based on the data of safety, tolerability, pharmacokinetics, and anti-tumor activity tested in Stage 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM95573, cetuximab
Description: Regimen: Expansion dose of HM95573 selected based on the data of safety and tolerability tested in Stage 1b
Study: NCT03482219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational therapy
Description: The Occupational therapy intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education. The home app intervention involves one session of education with the occupational therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home app intervention
Description: The app consists of videos depicting each exercise and ability to track adherence to exercises.
Study: NCT02423993

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QoL assessment
Description: For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):~1. The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.~2. The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Knowledge assessment
Description: For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
Study: NCT02336594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg
Study: NCT02552992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed Mind-Body Program
Study: NCT04487106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02683720

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ONS
Description: randomized clinical trial involving different ONS strategies

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ONS
Description: randomized clinical trial involving different ONS strategies
Study: NCT03652740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Effects of commonly used medications on mood and medication preference
Description: Capsules will contain a commonly prescribed or over-the-counter medication, or placebo. A placebo is an inactive substance that looks like the study drug, but contains no active drug. The capsules given in this study may include sedatives, muscle relaxants, or anti-anxiety medications, stimulant drugs/weight loss medications, and antihistamines. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. Participants will not be informed of the specific drugs they will receive during or after the study. Participants will not receive any drug that is not named as a possible study drug in the written informed consent form. All the study drugs to be administered are legally marketed in the United States.
Study: NCT02336594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Study: NCT00669656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostate Health Cocktail
Description: 3 capsules daily PO up 12 months
Study: NCT00415168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2, IV, every 21 days x 6 cycles
Study: NCT03622814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners at Meals
Description: The focus of the intervention is to facilitate meals using knowledge of the person with dementia's past history and lifelong preferences as well as their stage of disease, altering the behavior of the caregiver at meals to ameliorate dysfunctional behaviors, and altering the environment to make it more focused on the process of meals.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Condition
Description: Enhanced Usual Condition (EUC) Staff and volunteers at the EUC sites will receive training in communication between family and friends of the person with dementia. Following the general model of the Savvy Caregiver (Hepburn), communication training will occur every six months in these two sites. Families will be trained by project staff to record three meals including behavior at home each month. The Project Manager will attend the monthly support group for family members about communication. The administrator of the EUC RCC will be interviewed every 6 months the project is in place.
Study: NCT03523130

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Macrophage-specific inflammation

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Macrophage-specific inflammation
Study: NCT02858960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygen
Description: Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Venturi Mask
Description: Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
Study: NCT02336594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 2.5 mg
Study: NCT02197429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture